Site Group Page
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Site Group Page
 

Site Information
Pnk1 (human) T118-p TPESQPDtPPGTPLV Links 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142
Pnk1 (rat) T118-p TPGSPPDtPPGNPVD Links 12, 15, 22

Records

1

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54
24965592   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

6

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

7

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

8

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

9

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

10

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

11

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

12

Courcelles M, et al. (2013) Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions. Mol Syst Biol 9, 669
23712012   Curated Info

13

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

14

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

15

Biarc J, Chalkley RJ, Burlingame AL, Bradshaw RA (2012) The induction of serine/threonine protein phosphorylations by a PDGFR/TrkA chimera in stably transfected PC12 cells. Mol Cell Proteomics 11, 15-30
22027198   Curated Info

16

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

17

(2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[s/t/y](phosphorylation)
Curated Info

18

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

19

(2012) CST Curation Set: 13402; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[s/t/y](phosphorylation)
Curated Info

20

(2012) CST Curation Set: 13459; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[s/t/y](phosphorylation)
Curated Info

21

(2012) CST Curation Set: 13340; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

22

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

23

(2011) CST Curation Set: 12647; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

24

(2011) CST Curation Set: 12863; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

25

(2011) CST Curation Set: 12864; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

26

(2011) CST Curation Set: 12865; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

27

(2011) CST Curation Set: 12641; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

28

(2011) CST Curation Set: 12642; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

29

(2011) CST Curation Set: 12552; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

30

(2011) CST Curation Set: 12443; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

31

(2011) CST Curation Set: 12381; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

32

(2011) CST Curation Set: 12382; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

33

(2011) CST Curation Set: 12383; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

34

(2011) CST Curation Set: 12384; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

35

(2011) CST Curation Set: 12385; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

36

(2011) CST Curation Set: 12386; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

37

(2011) CST Curation Set: 12017; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

38

(2011) CST Curation Set: 12018; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

39

(2011) CST Curation Set: 12024; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

40

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

41

(2011) CST Curation Set: 11884; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

42

(2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[s/t/y](phosphorylation)
Curated Info

43

(2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[s/t/y](phosphorylation)
Curated Info

44

(2011) CST Curation Set: 11893; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin & pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[s/t/y](phosphorylation)
Curated Info

45

(2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S*/T*QG) Immunoaffinity Beads Cat#: 6969
Curated Info

46

(2011) CST Curation Set: 11298; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

47

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

48

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

49

(2010) CST Curation Set: 10875; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

50

(2010) CST Curation Set: 10710; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

51

(2010) CST Curation Set: 10711; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

52

(2010) CST Curation Set: 10723; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

53

(2010) CST Curation Set: 10689; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

54

(2010) CST Curation Set: 10686; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

55

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

56

(2010) CST Curation Set: 10300; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

57

(2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

58

(2010) CST Curation Set: 9968; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

59

(2010) CST Curation Set: 9970; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

60

(2010) CST Curation Set: 9975; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

61

(2010) CST Curation Set: 9969; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

62

(2010) CST Curation Set: 9973; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

63

(2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

64

(2010) CST Curation Set: 9974; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Millipore 05-368
Curated Info

65

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

66

(2010) CST Curation Set: 9862; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

67

(2010) CST Curation Set: 9867; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

68

(2010) CST Curation Set: 9870; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

69

(2010) CST Curation Set: 9869; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

70

(2010) CST Curation Set: 9868; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

71

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

72

(2010) CST Curation Set: 9850; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

73

(2010) CST Curation Set: 9852; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

74

(2010) CST Curation Set: 9824; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

75

(2010) CST Curation Set: 9831; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

76

(2010) CST Curation Set: 9835; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

77

(2010) CST Curation Set: 9842; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

78

(2010) CST Curation Set: 9832; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

79

(2010) CST Curation Set: 9848; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

80

(2010) CST Curation Set: 9847; Year: 2010; Biosample/Treatment: cell line, xy3-145N/untreated; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

81

(2010) CST Curation Set: 9851; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

82

(2010) CST Curation Set: 9853; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

83

(2010) CST Curation Set: 9829; Year: 2010; Biosample/Treatment: tissue, pancreas/untreated; Disease: pancreatic cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

84

(2010) CST Curation Set: 9849; Year: 2010; Biosample/Treatment: tissue, thyroid/untreated; Disease: thyroid cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

85

(2010) CST Curation Set: 9838; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

86

(2010) CST Curation Set: 9854; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

87

(2010) CST Curation Set: 9839; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

88

(2010) CST Curation Set: 9836; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

89

(2010) CST Curation Set: 9830; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

90

(2010) CST Curation Set: 9825; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

91

(2010) CST Curation Set: 9841; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

92

(2010) CST Curation Set: 9840; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

93

(2010) CST Curation Set: 9837; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

94

(2010) CST Curation Set: 9844; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

95

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

96

(2010) CST Curation Set: 9779; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

97

(2010) CST Curation Set: 9778; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

98

(2010) CST Curation Set: 9777; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

99

(2010) CST Curation Set: 9782; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

100

(2010) CST Curation Set: 9784; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

101

(2010) CST Curation Set: 9780; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

102

(2010) CST Curation Set: 9781; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

103

(2010) CST Curation Set: 9785; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

104

(2010) CST Curation Set: 9440; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

105

(2010) CST Curation Set: 9438; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

106

(2010) CST Curation Set: 9435; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

107

(2010) CST Curation Set: 9439; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

108

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

109

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

110

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

111

(2009) CST Curation Set: 7661; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

112

(2009) CST Curation Set: 7662; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

113

Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26
19664995   Curated Info

114

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

115

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

116

(2009) CST Curation Set: 6851; Year: 2009; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

117

(2009) CST Curation Set: 6922; Year: 2009; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

118

(2009) CST Curation Set: 6850; Year: 2009; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

119

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

120

(2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

121

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

122

(2008) CST Curation Set: 4609; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

123

(2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

124

(2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

125

(2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

126

Stokes MP, et al. (2007) Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A 104, 19855-60
18077418   Curated Info

127

(2007) CST Curation Set: 3481; Year: 2007; Biosample/Treatment: cell line, Jurkat/pervanadate & calyculin; Disease: T cell leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

128

Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6
17525332   Curated Info

129

(2006) CST Curation Set: 1954; Year: 2006; Biosample1/Treatment/Isotope: cell line, M059K/normal/L, Biosample2/Treatment/Isotope: cell line, M059K/UV/H; Disease: glioblastoma; SILAC: Y; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

130

(2006) CST Curation Set: 1824; Year: 2006; Biosample/Treatment: cell line, SEM/Flt3 inhibitor; Disease: acute lymphocytic leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-PXtP(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983
Curated Info

131

(2006) CST Curation Set: 1782; Year: 2006; Biosample/Treatment: cell line, HEL/-; Disease: erythroid leukemia; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)P(phosphorylation)
Curated Info

132

(2006) CST Curation Set: 1772; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

133

(2006) CST Curation Set: 1773; Year: 2006; Biosample/Treatment: cell line, GM00200/UV; Disease: -; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

134

(2006) CST Curation Set: 1614; Year: 2006; Biosample/Treatment: cell line, M059K/normal; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

135

(2006) CST Curation Set: 1616; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

136

(2006) CST Curation Set: 1617; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

137

(2006) CST Curation Set: 1122; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

138

(2006) CST Curation Set: 1123; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

139

(2006) CST Curation Set: 1091; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

140

(2006) CST Curation Set: 1092; Year: 2006; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

141

(2005) CST Curation Set: 909; Year: 2005; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

142

(2005) CST Curation Set: 908; Year: 2005; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.